戈舍瑞林联合比卡鲁胺间歇治疗对前列腺癌患者血清.pdf

《现代仪器与医疗》 2014年  第20卷   第2期 临床研究 戈舍瑞林联合比卡鲁胺间歇治疗对前列腺 癌患者血清VEGF和miR-34a的影响 李霖　韩晨东 （济南军区总医院内分泌科，济南　250031 ） [ 摘　要 ]　目的 ：探讨戈舍瑞林联合比卡鲁胺间歇治疗对前列腺癌患者血管内皮生长因子 （VEGF ）和miR-34a 的影响。方法 ：选择2007 年 12 月-2012 年6 月收治的晚期前列腺癌患者 83 例为研究对象，采用戈舍瑞林联合比卡鲁胺的间歇内分泌治疗，治疗9 个月后评价疗效。测 定治疗前后患者血清的VEGF 和miR-34a 。结果 ：患者的前列腺体积和血清前列腺特异性抗原 （PSA ）在治疗后均有明显减少，与治疗前比较差异显著（ 0.01 ）；前列腺体积变化率平均为 P 36.4% ，PSA 抑制率为63.6%。治疗后患者血清VEGF 均明显降低（ 0.01 ），治疗后血清miR- P 34a 明显升高（ 0.01 ）。结论 ：戈舍瑞林联合比卡鲁胺间歇内分泌治疗可以明显减少前列腺癌 P 血清VEGF ，提高miR-34a 的表达。 [ 关键词 ]　间歇治疗；前列腺癌；血管内皮生长因子；miR-34a 中图分类号：R737　文献标识码：B　文章编号：2055-5200（2014）02-045-03 DOI：10.11876/mimt201402013 Intermittent therapy of goserelin plus bicalutamide on serum VEGF and miR- 34a in patients with prostate cancer LI lin HAN Chen-dong. The department of 　 ， （ Endocrinology of Jinan Military Region General Hospital,JINAN 250031 ， ） [Abstract] Objective To study intermittent therapy of goserelin plus bicalutamide on serum 　 ： vascular endothelial growth factor(VEGF) and miR-34a in patients with prostate cancer. Methods ： From December 2007-June 2012, 83 patients with advanced prostate cancer were enrolled as an object of study. They were treated through goserelin plus bicalutamide for nine months. Serum VEGF and miR-34a before and after were detected. Results Patients of prostate volume and serum prostate- ： specific antigen (PSA) were significantly reduced after treatment, compared with before treatment significantly different (P 0.01). Prostate volume change rate averaged 36.4%, PSA inhibition rate was 63.6%. After treatment, serum VEGF was significantly lower (P 0.01), serum miR-34a was significantly higher ( 0.01). Co